Results 71 to 80 of about 2,984 (199)
Microbiology Spectrum, 2023 The use of valganciclovir as secondary prophylaxis for cytomegalovirus (CMV) infection in solid organ transplantation (SOT) is the most prevalent therapeutic choice, but it has been dismissed by the presence of resistance and toxicity.
Ana-Belén Pérez +7 more
doaj +1 more source
MedComm, Volume 7, Issue 4, April 2026.CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley +1 more source
Infectious Diseases and TherapyIntroduction In this single-center retrospective cohort study, we investigated the efficacy of letermovir in preventing Cytomegalovirus (CMV) infection in patients with aplastic anemia (AA) who have undergone allogeneic hematopoietic stem cell ...
Yuling Zhang +14 more
doaj +1 more source
American Journal of Hematology, Volume 101, Issue 2, Page 255-268, February 2026.ABSTRACT Polyfunctional cytomegalovirus (CMV)‐specific T cells are critical for antiviral immunity in allogeneic hematopoietic cell transplantation (HCT) recipients. However, gaps remain in managing refractory CMV and optimizing virus‐specific cellular therapy (VST).
Alicja Sadowska‐Klasa +9 more
wiley +1 more source
Unraveling Cytomegalovirus Drug Resistance in Transplant Patients by Targeting Deep Sequencing
Journal of Medical Virology, Volume 98, Issue 1, January 2026.ABSTRACT Drug‐resistant cytomegalovirus (CMV) poses a major clinical challenge in transplant recipients, leading to treatment failure and increased morbidity. This study applied a next‐generation sequencing (NGS) approach to identify antiviral resistance mutations (ARMs) in 71 samples from 68 CMV‐positive patients who had undergone hematopoietic stem ...
Salvador Alemán +7 more
wiley +1 more source
European Journal of Haematology, Volume 116, Issue 1, Page 14-22, January 2026.ABSTRACT Background Herpes zoster (HZ), resulting from reactivation of latent varicella‐zoster virus (VZV), imposes a significant burden on immunocompromised patients, particularly those with hematological malignancies and recipients of hematopoietic stem cell transplants (HSCT).
Enrica Antonia Martino +10 more
wiley +1 more source
The Changing Impact of Human Cytomegalovirus Serology and Infection on Patient Outcome After Allogeneic Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey in the Era of Letermovir Prophylaxis [PDF]
Background: In the letermovir primary prophylaxis (LET-PP) era, the epidemiology of human cytomegalovirus infection (HCMV-i) in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients has changed.
Baldanti, Fausto +29 more
core +1 more source
Intestinal and Multivisceral Transplantation: Where We Stand Today
Pediatric Transplantation, Volume 30, Issue 1, January 2026.ABSTRACT Intestinal and multivisceral transplantation has evolved from an experimental to a life‐saving procedure for children and adults with complications of gut failure (GF). Suboptimal long‐term outcomes of transplant elicit recent advances in surgical and medical gut rehabilitation along with the introduction of glucagon‐like peptide‐2 (GLP‐2 ...
Mohamed Maklad +5 more
wiley +1 more source
Scientific ReportsA key step in replication of human cytomegalovirus (HCMV) is the generation and packaging of unit-length genomes into preformed capsids. The enzymes involved in this process are viral terminases.
Lukas M. Kmetsch +2 more
doaj +1 more source
Recent advances in cytomegalovirus infection management in solid organ transplant recipients [PDF]
Purpose of review Human cytomegalovirus (CMV) continues to be the most important infectious complication following solid organ transplantation (SOT).
Grossi P. A., Peghin M.
core +1 more source